Análisis de los costes asociados a la administración intramuscular versus oral de la terapia antirretroviral en el manejo de la infección por el virus de la inmunodeficiencia humana
Vicente Estrada , Juan Emilio Losa , Ramón Morillo-Verdugo , Montserrat Pérez-Encinas , Jesús Santos , Antonio Castro , María Presa González , Laura Salinas-Ortega
{"title":"Análisis de los costes asociados a la administración intramuscular versus oral de la terapia antirretroviral en el manejo de la infección por el virus de la inmunodeficiencia humana","authors":"Vicente Estrada , Juan Emilio Losa , Ramón Morillo-Verdugo , Montserrat Pérez-Encinas , Jesús Santos , Antonio Castro , María Presa González , Laura Salinas-Ortega","doi":"10.1016/j.eimc.2024.07.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Objetive</h3><div>To identify and analyze the resources and costs associated with the administration of intramuscular antiretroviral therapy (ART) cabotegravir<!--> <!-->+<!--> <!-->rilpivirine (CAB<!--> <!-->+<!--> <!-->RPV) compared to oral ART in the management of Human Immunodeficiency Virus Type 1 (HIV-1) infection in Spain.</div></div><div><h3>Methods</h3><div>An economic model was developed to identify resources and analyze costs from the perspective of the National Health System (NHS) and societal, associated with the administration of intramuscular ART (CAB<!--> <!-->+<!--> <!-->RPV) compared to oral ART over a two-year time horizon. Costs included treatment change monitoring, pharmaceutical dispensation, administration, management of adverse events to injection-site reactions (AEs-ISR), travel to the hospital, telepharmacy service, and lost work productivity. Unit costs (€, 2023) were obtained from the literature. Sensitivity analyses were conducted to evaluate the robustness of the model.</div></div><div><h3>Results</h3><div>Intramuscular ART compared to oral ART was associated with an increase in costs of €673.16/patient over two years from the perspective of the NHS, and €719.59/patient from the social perspective. Intramuscular ART would generate increased costs for dispensation (+€97.75), administration (+€394.55), monitoring (+€288.74), management of AEs-ISR (+€6.46), travel (+€8.36), and lost work productivity (+€38.07), compared to oral ART administration.</div></div><div><h3>Conclusion</h3><div>Treating HIV-1 with intramuscular CAB<!--> <!-->+<!--> <!-->RPV leads to increased resource consumption and costs, compared to oral ART.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 5","pages":"Pages 251-259"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213005X24002908","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Objetive
To identify and analyze the resources and costs associated with the administration of intramuscular antiretroviral therapy (ART) cabotegravir + rilpivirine (CAB + RPV) compared to oral ART in the management of Human Immunodeficiency Virus Type 1 (HIV-1) infection in Spain.
Methods
An economic model was developed to identify resources and analyze costs from the perspective of the National Health System (NHS) and societal, associated with the administration of intramuscular ART (CAB + RPV) compared to oral ART over a two-year time horizon. Costs included treatment change monitoring, pharmaceutical dispensation, administration, management of adverse events to injection-site reactions (AEs-ISR), travel to the hospital, telepharmacy service, and lost work productivity. Unit costs (€, 2023) were obtained from the literature. Sensitivity analyses were conducted to evaluate the robustness of the model.
Results
Intramuscular ART compared to oral ART was associated with an increase in costs of €673.16/patient over two years from the perspective of the NHS, and €719.59/patient from the social perspective. Intramuscular ART would generate increased costs for dispensation (+€97.75), administration (+€394.55), monitoring (+€288.74), management of AEs-ISR (+€6.46), travel (+€8.36), and lost work productivity (+€38.07), compared to oral ART administration.
Conclusion
Treating HIV-1 with intramuscular CAB + RPV leads to increased resource consumption and costs, compared to oral ART.
期刊介绍:
Hoy está universalmente reconocida la renovada y creciente importancia de la patología infecciosa: aparición de nuevos agentes patógenos, de cepas resistentes, de procesos con expresión clínica hasta ahora desconocida, de cuadros de una gran complejidad. Paralelamente, la Microbiología y la Infectología Clínicas han experimentado un gran desarrollo como respuesta al reto planteado por la actual patología infecciosa. Enfermedades Infecciosas y Microbiología Clínica es la Publicación Oficial de la Sociedad Española SEIMC. Cumple con la garantía científica de esta Sociedad, la doble función de difundir trabajos de investigación, tanto clínicos como microbiológicos, referidos a la patología infecciosa, y contribuye a la formación continuada de los interesados en aquella patología mediante artículos orientados a ese fin y elaborados por autores de la mayor calificación invitados por la revista.